See more : Glenveagh Properties PLC (GVR.IR) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaTher Holdings Ltd. (PHRRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaTher Holdings Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Northern Minerals Limited (NOURF) Income Statement Analysis – Financial Results
- Expand Energy Corporation (EXE) Income Statement Analysis – Financial Results
- Advanced Micro Devices, Inc. (AMD.NE) Income Statement Analysis – Financial Results
- TOA Oil Co., Ltd. (TOAOF) Income Statement Analysis – Financial Results
- Equinor ASA (EQNR.OL) Income Statement Analysis – Financial Results
PharmaTher Holdings Ltd. (PHRRF)
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.42K | 1.78K | 355.00 | 0.00 |
| Gross Profit | 0.00 | -1.42K | -1.78K | -355.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.14M | 3.02M | 2.61M | 751.54K | 0.00 |
| General & Administrative | 904.37K | 941.72K | 1.36M | 1.68M | 142.90K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 23.67K |
| SG&A | 904.37K | 941.72K | 1.36M | 1.68M | 23.82K |
| Other Expenses | 0.00 | 24.99K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.04M | 4.01M | 4.10M | 2.82M | 23.82K |
| Cost & Expenses | 3.04M | 4.01M | 4.10M | 2.82M | 23.82K |
| Interest Income | 0.00 | 206.82K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 711.00 | 1.42K | 1.78K | 355.00 | 142.90K |
| EBITDA | -3.04M | -3.96M | -3.96M | -2.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.04M | -1.38M | -3.97M | -8.52M | -23.82K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -71.26K | -2.46M | -274.03K | 5.32M | 0.00 |
| Income Before Tax | -3.12M | -6.42M | -4.24M | 2.89M | -23.82K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.43M | -225.05K | 225.05K | -142.90 |
| Net Income | -3.12M | -6.42M | -4.01M | 2.66M | -23.82K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.07 | -0.05 | 0.04 | 0.00 |
| EPS Diluted | -0.04 | -0.07 | -0.05 | 0.04 | 0.00 |
| Weighted Avg Shares Out | 88.23M | 88.17M | 81.11M | 64.56M | 34.08M |
| Weighted Avg Shares Out (Dil) | 88.23M | 88.17M | 81.11M | 73.26M | 34.08M |
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
PharmaTher Provides Update for Expected FDA Approval of Ketamine
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
Source: https://incomestatements.info
Category: Stock Reports